Outlook Therapeutics Wins FDA Approval for Wet AMD Drug After Three CRLs

By FieldPulse Staff · May 27, 2026

Tags: FDA, approval, launch, ophthalmology, clinical trials

Outlook Therapeutics secured FDA approval for its wet AMD treatment after three complete response letters, ending a long regulatory cycle for the company.

Outlook Therapeutics has received FDA approval for its wet AMD treatment after previously receiving three complete response letters from the agency.

The decision closes out one of the more difficult regulatory paths in ophthalmology and gives the company a commercial opening in a competitive retinal market.

The central development is the approval itself.

The practical question now is whether Outlook can execute on launch, physician adoption, and positioning against more established retina products.